Form 4 for SLDB Solid Biosciences Inc.

Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-02 · accession 0000899243-22-037681 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-12-05	2022-12-02	SLDB	Cumbo Alexander	Pres, CEO, Dir	A - Grant	—	+584	584	New	—
DM	2022-12-05	2022-12-02	SLDB	Cumbo Alexander	Pres, CEO, Dir	A - Grant	$0.00	+343.3K	114.4K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-02	A	A	584	—	584	D	—	—	(F1) The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.
2	Derivative	Stock Option (Right to Buy)	2022-12-02	A	A	228,900	$0.00	228,900	D	$6.77 · — to 2032-12-02	228,900 Common Stock	(F2) This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.
3	Derivative	Restricted Stock Units	2022-12-02	A	A	114,449	$0.00	114,449	D	— · — to —	114,449 Common Stock	(F3) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). (F4) The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.